These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28800336)

  • 21. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment.
    Merlini L; Cecconi I; Parmeggiani A; Cordelli DM; Dormi A
    Acta Myol; 2020 Dec; 39(4):200-206. PubMed ID: 33458575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study.
    Reitter B
    Brain Dev; 1995; 17 Suppl():39-43. PubMed ID: 8882570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
    Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
    Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parents' Reactions to the Diagnosis of Duchenne Muscular Dystrophy: Associations Between Resolution, Family Functioning, and Child Behavior Problems.
    Baiocco R; Castelli Gattinara P; Cioccetti G; Ioverno S
    J Nurs Res; 2017 Dec; 25(6):455-463. PubMed ID: 29099477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
    Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
    J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database.
    Koeks Z; Bladen CL; Salgado D; van Zwet E; Pogoryelova O; McMacken G; Monges S; Foncuberta ME; Kekou K; Kosma K; Dawkins H; Lamont L; Bellgard MI; Roy AJ; Chamova T; Guergueltcheva V; Chan S; Korngut L; Campbell C; Dai Y; Wang J; Barišić N; Brabec P; Lähdetie J; Walter MC; Schreiber-Katz O; Karcagi V; Garami M; Herczegfalvi A; Viswanathan V; Bayat F; Buccella F; Ferlini A; Kimura E; van den Bergen JC; Rodrigues M; Roxburgh R; Lusakowska A; Kostera-Pruszczyk A; Santos R; Neagu E; Artemieva S; Rasic VM; Vojinovic D; Posada M; Bloetzer C; Klein A; Díaz-Manera J; Gallardo E; Karaduman AA; Oznur T; Topaloğlu H; El Sherif R; Stringer A; Shatillo AV; Martin AS; Peay HL; Kirschner J; Flanigan KM; Straub V; Bushby K; Béroud C; Verschuuren JJ; Lochmüller H
    J Neuromuscul Dis; 2017; 4(4):293-306. PubMed ID: 29125504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
    Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosocial adjustment and parental stress in Duchenne Muscular Dystrophy.
    Gocheva V; Schmidt S; Orsini AL; Hafner P; Schaedelin S; Weber P; Fischer D
    Eur J Paediatr Neurol; 2019 Nov; 23(6):832-841. PubMed ID: 31585833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.
    Moxley RT; Pandya S; Ciafaloni E; Fox DJ; Campbell K
    J Child Neurol; 2010 Sep; 25(9):1116-29. PubMed ID: 20581335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pain experience, expression and coping in boys and young men with Duchenne Muscular Dystrophy - A pilot study using mixed methods.
    Hunt A; Carter B; Abbott J; Parker A; Spinty S; deGoede C
    Eur J Paediatr Neurol; 2016 Jul; 20(4):630-8. PubMed ID: 27053141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
    Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
    Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
    Bello L; Gordish-Dressman H; Morgenroth LP; Henricson EK; Duong T; Hoffman EP; Cnaan A; McDonald CM;
    Neurology; 2015 Sep; 85(12):1048-55. PubMed ID: 26311750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Becoming a back-up carer: parenting sons with Duchenne muscular dystrophy transitioning into adulthood.
    Yamaguchi M; Suzuki M
    Neuromuscul Disord; 2015 Jan; 25(1):85-93. PubMed ID: 25435264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing mental health in boys with Duchenne muscular dystrophy: Emotional, behavioural and neurodevelopmental profile in an Italian clinical sample.
    Colombo P; Nobile M; Tesei A; Civati F; Gandossini S; Mani E; Molteni M; Bresolin N; D'Angelo G
    Eur J Paediatr Neurol; 2017 Jul; 21(4):639-647. PubMed ID: 28392227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys.
    Heutinck L; Kampen NV; Jansen M; Groot IJ
    J Child Neurol; 2017 Apr; 32(5):450-457. PubMed ID: 28112012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
    Dooley JM; Bobbitt SA; Cummings EA
    Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
    Mayo AL; Craven BC; McAdam LC; Biggar WD
    Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
    Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
    Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vertebral fractures in boys with Duchenne muscular dystrophy.
    Bothwell JE; Gordon KE; Dooley JM; MacSween J; Cummings EA; Salisbury S
    Clin Pediatr (Phila); 2003 May; 42(4):353-6. PubMed ID: 12800730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.